She embarked on an extraordinary journey for Cancer Treatment for GBM in 2022, a 56-year-old female patient from East Asia faced the daunting diagnosis of Glioblastoma, specifically the aggressive GBM WHO 4. Her medical history narrates a saga of surgery to combat the ominous brain tumour, while her unwavering spirit expressed a fervent desire to explore complementary treatment options alongside radiotherapy. This odyssey commenced with ECCT in February 2022.
她在2022年踏上了一段非凡的旅程，来自东亚的一位56岁女性患者面临了令人生畏的胶质母细胞瘤诊断，具体是侵袭性的GBM WHO 4。她的病史叙述了一段与邪恶的脑瘤搏斗的传奇，而她坚韧不拔的精神表达出了对放射治疗之外的辅助治疗选择的热切渴望。这段奥德赛始于2022年2月，与ECCT相伴而行。Glioblastomas, notorious for their high malignancy as grade 4 tumours, are distinguished by their rapid cell division and aberrant blood supply. They predominantly comprise abnormal astrocytic cells, with a notorious ability to infiltrate neighbouring brain regions. In dire cases, they can even spread to the opposite side of the brain through connecting fibres. The chronicle of this patient's journey with ECCT commenced in February 2022, illuminating a path of hope amid uncertainty.
胶质母细胞瘤以其高度恶性的4级肿瘤而声名狼藉，以其快速的细胞分裂和异常的血液供应而著称。它们主要由异常的星形胶质细胞组成，以入侵邻近脑区域的能力而臭名昭著。在极端情况下，它们甚至可以通过连接纤维传播到大脑的对侧。这位患者与ECCT的旅程在2022年2月开始，为不确定性中的希望照亮了一条道路。Across three months, a remarkable transformation unfolded, witnessed not only in her physical condition but also in the MRI assessments conducted at the surgery site. The tumour mass, originally measured at a formidable 4.5 cm, displayed an astonishing reduction to a mere 2 cm, while two nodules stood firm with only slight growth. These findings indeed provide an encouraging narrative when ECCT is combined with radiotherapy in the battle against glioblastoma.
在三个月的时间里，一个引人注目的转变展现出来，不仅体现在她的身体状况上，还体现在手术部位进行的MRI评估中。最初被测量为强大的4.5厘米的肿瘤质量显示出令人惊讶的减小，仅为2厘米，而两个结节仅略有生长。当ECCT与放射治疗结合应对胶质母细胞瘤时，这些发现确实提供了一个鼓舞人心的叙述。Of exceptional note is the tumour's favourable response to ECCT, a beacon of hope in the face of such a formidable adversary. Within the initial 3-4 months of ECCT application, a substantial reduction in the tumour's size transpired. The remarkable decrease from 4.5 cm to 2 cm in the right temporo-parietal region stands as a beacon of promise. This progress, initiated within a month of merging ECCT with radiotherapy, showcases a beacon of hope, albeit with a minor, stable growth of cells in the right parietal area.
值得特别注意的是肿瘤对ECCT的良好反应，这是在面对如此强大的对手时的希望之光。在ECCT应用的最初3-4个月内，肿瘤体积显著减小。在右颞顶叶区域，从4. 5厘米减小到2厘米的显著减少尤为引人瞩目。这一进展在将ECCT与放射治疗结合一个月后开始，尽管在右顶叶区域的细胞仍有轻微但稳定的生长。The saga of this patient's journey against glioblastoma is not merely motivating but a testament to resilience, hope, and the unyielding pursuit of healing. It's a tale of courage in the face of adversity, a glimmer of triumph amidst the darkness.
这位患者抗击胶质母细胞瘤的旅程不仅仅是激励人心，更是对坚韧、希望和不懈追求康复的见证。这是一部在逆境中的勇气之歌，是黑暗中的一丝胜利之光。
Comments